@article {43999,
	title = {Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study.},
	journal = {EClinicalMedicine},
	volume = {59},
	year = {2023},
	month = {2023 May},
	pages = {101951},
	abstract = {BACKGROUND: Gallbladder cancer (GBC) is rare but aggressive. The extent of surgical intervention for different GBC stages is non-uniform, ranging from cholecystectomy alone to extended resections including major hepatectomy, resection of adjacent organs and routine extrahepatic bile duct resection (EBDR). Robust evidence here is lacking, however, and survival benefit poorly defined. This study assesses factors associated with recurrence-free survival (RFS), overall survival (OS) and morbidity and mortality following GBC surgery in high income countries (HIC) and low and middle income countries (LMIC).

METHODS: The multicentre, retrospective Operative Management of Gallbladder Cancer (OMEGA) cohort study included all patients who underwent GBC resection across 133 centres between 1st January 2010 and 31st December 2020. Regression analyses assessed factors associated with OS, RFS and morbidity.

FINDINGS: On multivariable analysis of all 3676 patients, wedge resection and segment IVb/V resection failed to improve RFS (HR 1.04 [0.84-1.29], p~=~0.711 and HR 1.18 [0.95-1.46], p~=~0.13 respectively) or OS (HR 0.96 [0.79-1.17], p~=~0.67 and HR 1.48 [1.16-1.88], p~=~0.49 respectively), while major hepatectomy was associated with worse RFS (HR 1.33 [1.02-1.74], p~=~0.037) and OS (HR 1.26 [1.03-1.53], p~=~0.022). Furthermore, EBDR (OR 2.86 [2.3-3.52], p~<~0.0010), resection of additional organs (OR 2.22 [1.62-3.02], p~<~0.0010) and major hepatectomy (OR 3.81 [2.55-5.73], p~<~0.0010) were all associated with increased morbidity and mortality. Compared to LMIC, patients in HIC were associated with poorer RFS (HR 1.18 [1.02-1.37], p~=~0.031) but not OS (HR 1.05 [0.91-1.22], p~=~0.48). Adjuvant and neoadjuvant treatments were infrequently used.

INTERPRETATION: In this large, multicentre analysis of GBC surgical outcomes, liver resection was not conclusively associated with improved survival, and extended resections were associated with greater morbidity and mortality without oncological benefit. Aggressive upfront resections do not benefit higher stage GBC, and international collaborations are needed to develop evidence-based neoadjuvant and adjuvant treatment strategies to minimise surgical morbidity and prioritise prognostic benefit.

FUNDING: Cambridge Hepatopancreatobiliary Department Research Fund.},
	issn = {2589-5370},
	doi = {10.1016/j.eclinm.2023.101951},
	author = {Balakrishnan, Anita and Barmpounakis, Petros and Demiris, Nikolaos and Jah, Asif and Spiers, Harry V M and Talukder, Shibojit and Martin, Jack L and Gibbs, Paul and Harper, Simon J F and Huguet, Emmanuel L and Kosmoliaptsis, Vasilis and Liau, Siong S and Praseedom, Raaj K and Basu, Bristi and de Aretxabala, Xavier and Lendoire, Javier and Maithel, Shishir and Branes, Alejandro and Andersson, Bodil and Serrablo, Alejandro and Adsay, Volkan}
}
